In April, Synpromics attended the 6th annual Alliance for Regenerative Medicine Cell & Gene Therapy Investor Day in New York, a full-day conference featuring discussions between key opinion leaders, top analysts and senior executives in addition to presentations by the field’s most promising companies. Whilst there, David Venables, CEO of Synpromics, presented to potential investors and fellow biotech professionals. 

Synpromics has recently announced the award of grants from Scottish Enterprise and Innovate UK which contribute towards a £5.4m R&D programme to further develop its PromPT® platform and create novel inducible promoter systems that can be applied across the biotechnology sector. David discussed Synpromics’ recent developments and future plans as well as answering questions on gene therapy, the future of cell and gene medicine, Synpromics’ partners and what Synpromics is doing differently in the synthetic promoter space.

Watch David's full presentation below.